NO20015054L - Drugs comprising inhibitors of cell volume-regulated human kinase H-SGK - Google Patents

Drugs comprising inhibitors of cell volume-regulated human kinase H-SGK

Info

Publication number
NO20015054L
NO20015054L NO20015054A NO20015054A NO20015054L NO 20015054 L NO20015054 L NO 20015054L NO 20015054 A NO20015054 A NO 20015054A NO 20015054 A NO20015054 A NO 20015054A NO 20015054 L NO20015054 L NO 20015054L
Authority
NO
Norway
Prior art keywords
sgk
inhibitors
drugs
cell volume
human kinase
Prior art date
Application number
NO20015054A
Other languages
Norwegian (no)
Other versions
NO20015054D0 (en
Inventor
Siegfried Waldegger
Carsten Wagner
Stefan Broeer
Karin Klingel
Original Assignee
Lang Florian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lang Florian filed Critical Lang Florian
Publication of NO20015054D0 publication Critical patent/NO20015054D0/en
Publication of NO20015054L publication Critical patent/NO20015054L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
NO20015054A 1999-04-20 2001-10-17 Drugs comprising inhibitors of cell volume-regulated human kinase H-SGK NO20015054L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19917990A DE19917990A1 (en) 1999-04-20 1999-04-20 Medicament containing inhibitors of cell volume regulated human kinase h-sgk
PCT/EP2000/003578 WO2000062781A1 (en) 1999-04-20 2000-04-19 Medicaments containing inhibitors of cell-volume regulated human kinase h-sgk

Publications (2)

Publication Number Publication Date
NO20015054D0 NO20015054D0 (en) 2001-10-17
NO20015054L true NO20015054L (en) 2001-12-14

Family

ID=7905297

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015054A NO20015054L (en) 1999-04-20 2001-10-17 Drugs comprising inhibitors of cell volume-regulated human kinase H-SGK

Country Status (18)

Country Link
EP (1) EP1171131A1 (en)
JP (1) JP2002542196A (en)
KR (1) KR100718900B1 (en)
CN (1) CN1351496A (en)
AU (1) AU779941B2 (en)
BR (1) BR0009914A (en)
CA (1) CA2369078A1 (en)
CZ (1) CZ20013778A3 (en)
DE (1) DE19917990A1 (en)
HU (1) HUP0200819A3 (en)
MX (1) MXPA01010588A (en)
NO (1) NO20015054L (en)
PL (1) PL198427B1 (en)
RU (1) RU2288718C9 (en)
SK (1) SK14972001A3 (en)
UA (1) UA79066C2 (en)
WO (1) WO2000062781A1 (en)
ZA (1) ZA200108610B (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10042137A1 (en) * 2000-08-28 2002-03-14 Florian Lang sgk2 and sgk3 as diagnostic and therapeutic targets
DE10113876A1 (en) * 2001-03-21 2002-09-26 Eberhard Karls Uni Medizinisch Quantitative diagnosis of genetically related hypertension, by correlating blood pressure with overexpression or modification of human sgk family proteins
DE60233398D1 (en) 2001-04-27 2009-10-01 Cold Spring Harbor Lab REDUCTION OF MEMORY DEFICITS AND MEMORY COMPONENTS OF PSYCHIATRIC FUNCTIONAL DISORDERS BY CHANGING ATYPICAL PKM ACTIVITY
DE10149393A1 (en) * 2001-09-28 2003-04-24 Florian Lang Detecting the expression of serum and glucocorticoid-dependent kinase-1 (sgk1), for diagnosing coagulative diseases, diabetes, tumors, diabetes and autoimmune diseases, comprises using an antibody against sgk1
DE10225844A1 (en) * 2002-06-04 2003-12-18 Lang Florian sgk and nedd as diagnostic and therapeutic targets
DE10305212A1 (en) * 2003-02-07 2004-08-19 Florian Prof. Dr.med. Lang Use of the sgk gene family for the diagnosis and therapy of cataracts and glaucoma
KR101032281B1 (en) * 2003-03-03 2011-05-06 플로리안 랑 Sgk1 as diagnostic and therapeutic target
WO2004084889A1 (en) * 2003-03-28 2004-10-07 Pfizer Inc. Use of protein kinase c inhibitor for suppressing sustained slow postsynaptic excitation (sspe) of enteric neurons
DE10346913A1 (en) 2003-10-09 2005-05-04 Merck Patent Gmbh acylhydrazone
WO2005084702A1 (en) * 2004-03-02 2005-09-15 Hokkaido Technology Licensing Office Co., Ltd. Agent for preventing and treating organ fibrosis
KR20070015149A (en) * 2004-03-11 2007-02-01 메르크 파텐트 게엠베하 Methods for interfering with fibrosis
KR20070015148A (en) * 2004-03-11 2007-02-01 메르크 파텐트 게엠베하 Methods for modulating glutamate receptors for treating neuropsychiatric disorders comprising the use of modulators of serum and glucocorticoid inducible kinases
WO2005106491A2 (en) * 2004-04-30 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase 1 (sgk1)
WO2005118832A2 (en) * 2004-06-01 2005-12-15 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase-like protein (sgkl)
DE102004030987A1 (en) * 2004-06-26 2006-01-12 Merck Patent Gmbh Ortho-substituted (3-hydroxyphenyl) -acetic acid benzylidene hydrazides
MX2007001155A (en) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Methods, systems, and computer program products for providing presence gateway functionality in a telecommunications network.
DE102005001053A1 (en) * 2005-01-07 2006-07-20 Merck Patent Gmbh Square acid derivatives
DE102005015255A1 (en) * 2005-04-04 2006-10-05 Merck Patent Gmbh New acylhydrazide compounds are signal transduction kinase inhibitor, useful for treating and/or preventing diseases, e.g. diabetes, adiposity, metabolic syndrome, cancer and tumor cells
DE102005035742A1 (en) * 2005-07-29 2007-02-01 Merck Patent Gmbh New cyclobut-3-ene-1,2-dione derivatives are kinase inhibitors useful for treating e.g. cancer, hypertension, diabetes, glaucoma and bacterial infections
DE102005039541A1 (en) * 2005-08-22 2007-03-22 Merck Patent Gmbh 3-oxo-indazol-square acid derivatives
DE102007002717A1 (en) 2007-01-18 2008-07-24 Merck Patent Gmbh Heterocyclic indazole derivatives
DE102007022565A1 (en) 2007-05-14 2008-11-20 Merck Patent Gmbh Heterocyclic indazole derivatives
EP2014651A1 (en) * 2007-07-12 2009-01-14 Exonhit Therapeutics SA Compounds and methods for modulating Rho GTPases
DE102008010363A1 (en) 2008-02-18 2009-08-20 Lang, Florian, Prof. Dr.med. Sgk1 as a therapeutic and diagnostic target for carcinomatous diseases
DE102008010361A1 (en) 2008-02-18 2009-08-20 Merck Patent Gmbh sgk1 inhibitors for the prophylaxis and / or therapy of viral diseases and / or carcinomas
DE102008010362A1 (en) * 2008-02-18 2009-08-20 Florian Prof. Dr. Lang Sgk1 as a therapeutic and diagnostic target for viral diseases
DE102008029072A1 (en) * 2008-06-10 2009-12-17 Lang, Florian, Prof. Dr.med. Substance, which inhibits serum and glucocorticoid dependent kinase 3, useful for the prophylaxis and/or treatment or diagnosis of age-related diseases e.g. arteriosclerosis, skin atrophy, myasthenia, infertility, stroke and kyphosis
DE102008038222A1 (en) 2008-08-18 2010-02-25 Merck Patent Gmbh Indazol-5-carboxylic acid derivatives
DE102008038221A1 (en) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-azaindole derivatives
DE102008038220A1 (en) 2008-08-18 2010-02-25 Merck Patent Gmbh oxadiazole
DE102008059133A1 (en) 2008-11-26 2010-05-27 Merck Patent Gmbh Difluorophenyl diacylhydrazide derivatives
US8802099B2 (en) 2010-11-10 2014-08-12 National Jewish Health Methods to treat allergic conditions
CN107875153A (en) * 2017-11-16 2018-04-06 上海壹志医药科技有限公司 The medicinal usage of Des-N-methylchelerythrine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373501A (en) * 1976-12-11 1978-06-30 Kitasato Inst Novel antibiotics amm2282 and process for preparing same
US5242397A (en) * 1989-06-20 1993-09-07 Cedars-Sinai Medical Center Catheter device and method of use for intramural delivery of protein kinase C and tyrosine protein kinase inhibitors to prevent restenosis after balloon angioplasty
US5137912A (en) * 1991-01-28 1992-08-11 National Science Council Of Republic Of China Chelerythrine inhibits platelet aggregation--a potential anti-aggregation drug
GB9325395D0 (en) * 1993-12-11 1994-02-16 Ciba Geigy Ag Compositions
US5874464A (en) * 1995-01-13 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Conformationally constrained diacylglycerol analogues
WO1997007081A2 (en) * 1995-08-11 1997-02-27 Yale University Glycosylated indolocarbazole synthesis
WO1997045397A1 (en) * 1996-05-30 1997-12-04 Hoechst Marion Roussel, Inc. Alkyloxyamino substituted fluorenones and their use as protein kinase c inhibitors
EP0887081B1 (en) * 1997-06-27 2003-04-23 Smithkline Beecham Corporation Human serum glucocorticoid regulated kinase, a target for chronic renal disease and diabetic nephropathy
EP0889127A1 (en) * 1997-07-01 1999-01-07 Smithkline Beecham Corporation Serine/threonine protein kinase (H-SGK2)
CO4940430A1 (en) * 1997-07-07 2000-07-24 Novartis Ag POLYCLIC COMPOUNDS CONTAINING HYDROGENATED STAUROSPORIN WITH CONVENIENT PHARMACOLOGICAL PROPERTIES AND AN INHIBITING EFFECT ON THE GROWTH OF TUMOR CELLS

Also Published As

Publication number Publication date
RU2288718C2 (en) 2006-12-10
NO20015054D0 (en) 2001-10-17
RU2288718C9 (en) 2008-04-27
CA2369078A1 (en) 2000-10-26
CZ20013778A3 (en) 2002-06-12
HUP0200819A3 (en) 2009-08-28
KR20020012172A (en) 2002-02-15
AU4297200A (en) 2000-11-02
EP1171131A1 (en) 2002-01-16
BR0009914A (en) 2002-01-08
SK14972001A3 (en) 2002-06-04
PL352547A1 (en) 2003-08-25
DE19917990A1 (en) 2000-11-02
KR100718900B1 (en) 2007-05-17
JP2002542196A (en) 2002-12-10
HUP0200819A2 (en) 2002-07-29
UA79066C2 (en) 2007-05-25
ZA200108610B (en) 2002-01-02
MXPA01010588A (en) 2004-09-06
CN1351496A (en) 2002-05-29
WO2000062781A1 (en) 2000-10-26
PL198427B1 (en) 2008-06-30
AU779941B2 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
NO20015054L (en) Drugs comprising inhibitors of cell volume-regulated human kinase H-SGK
HUP0301005A3 (en) Pirrolotriazine inhibitors of kinases pharmaceutical compositions containing them and their use
HUP0203323A3 (en) Tyrosine kinase inhibitors and pharmaceutical compositions containing them
ATE306487T1 (en) PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IKB-ALPHA
HUP0201261A3 (en) Indole-type derivatives as inhibitors of p38 kinase and pharmaceutical compositions containing them
HUP0202682A3 (en) Tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use
ATE380814T1 (en) KINASE INHIBITORS AS MEDICINAL PRODUCTS
NO20022864L (en) Aminothiazole inhibitors of cyclin independent kinase
AU2728201A (en) 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
NO20013335D0 (en) Use of 4-H-1-benzopyran-4-one derivatives as smooth muscle cell proliferation inhibitors
NO20014858D0 (en) Use of CYP2D6 inhibitors in combination therapy
HUP0202708A3 (en) Cyclic protein tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use
NO20000225D0 (en) Retarded drug formulations containing a combination of an opioid and an agonist
HUP0302615A3 (en) Kinase inhibitor quinazoline derivatives and pharmaceutical compositions containing them and their use
EE200100659A (en) Diaminothiazoles and their use for the inhibition of protein kinases
PL338991A1 (en) Substituted oxindole derivatives as inhibitors of thyrosine kinase protein and serine/threonine kinase protein
CY2013009I1 (en) INDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES AND METHODS OF THEIR USE
EE200200140A (en) Pteridinones as kinase inhibitors
HUP0201214A2 (en) Inhibitors of impdh enzyme, pharmaceutical compositions containing them and their use
ID22565A (en) USE OF NANODISPERION IN FINAL DRUG FORMULATION
HUP0300318A3 (en) Pyrazolobenzodiazepines as cdk2 inhibitors and pharmaceutical compositions containing them and their use
ATE315383T1 (en) COATING OF TABLET CORE
NO20020365L (en) Oligonucleotides for inhibiting the expression of human eg5
ATE234840T1 (en) 1-AMINOTRIAZOLO 4,3-A QUINAZOLIN-5-ONE AND/OR - THIONE INHIBITORS OF PHOSPHODIESTERASES IV
HUP0202401A2 (en) Five-membered heterocyclic amidinec as prodrugs of thrombin inhibitors, pharmaceutical compositions comprising thereof and their use

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application